C. difficile infection: extent of the problem and associated costs

Laura Fascio Pecetto

DOI: https://doi.org/10.7175/cmi.v9i1S.1161

Full Text:

HTML PDF

References

  • Davies KA, Longshaw CM, Davis GL, et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis 2014; 14: 1208-19; http://dx.doi.org/10.1016/S1473-3099(14)70991-0
  • Crobach MJ, Dekkers OM, Wilcox MH, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009; 15: 1053-66; http://dx.doi.org/10.1111/j.1469-0691.2009.03098.x
  • Magalini S, Pepe G, Panunzi S, et al. An economic evaluation of Clostridium difficile infection management in an Italian hospital environment. Eur Rev Med Pharmacol Sci 2012; 16: 2136-41
  • Nathwani D, Cornely OA, Van Engen AK, et al. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother 2014; 69: 2901-12; http://dx.doi.org/10.1093/jac/dku257
  • Cornely OA, Crook DW, Esposito R, et al; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012 ;12: 281-9; http://dx.doi.org/10.1016/S1473-3099(11)70374-7
  • Louie TJ, Miller MA, Mullane KM, et al; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31; http://dx.doi.org/10.1056/NEJMoa0910812

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


© SEEd srl